# Ribitol PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ribitol

> The PDUFA target action date for ribitol, sponsored by BridgeBio Pharma, Inc. (BBIO), is November 27, 2026. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: year only, month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ribitol PDUFA date?

The PDUFA target action date for ribitol, sponsored by BridgeBio Pharma, Inc. (BBIO), is November 27, 2026. Status: scheduled. Press release filed with the SEC (EX-99): "- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review." Last confirmed October 29, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/ribitol)

Source: Press release filed with the SEC (EX-99), accession 0001743881-26-000033, https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/pdufa/ribitol#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ribitol |
| Codes | BBP-418 |
| Sponsor | BridgeBio Pharma, Inc. (BBIO) https://sec-api.dev/companies/bbio/catalysts |
| Indications | lgmd2i/r9, with topline data readout |
| Modality |  |
| FDA designations | fast track, orphan, priority review |

## Timeline

### 2025: topline data readout

- Status: scheduled. Date confidence: year. Stage: 3. Indication: LGMD2I/R9, with topline data readout.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124576): "BridgeBio completed enrollment of FORTIFY, the Company's Phase 3 registrational study of BBP-418 in individuals with LGMD2I/R9, with topline data readout from the interim analysis expected in 2025." https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm

### Oct 2025: topline data readout

- Status: completed, met. Date confidence: month. Stage: 3.
- First seen 2026-02-24, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0001743881-26-000009): "•Positive Phase 3 results for BBP-418 in LGMD2I/R9: In October 2025, we presented Topline data from the Phase 3 FORTIFY study showed BBP-418 achieved its primary and key secondary endpoints in limb-girdle muscular dystrophy type 2I/R9." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm
- SEC Form 10-K (accession 0001743881-26-000009): "In October 2025, we reported positive topline results from the planned interim analysis of FORTIFY, a global, randomized, double-blind, placebo-controlled Phase 3 study evaluating BBP-418 in individuals with LGMD2I/R9." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-10-27, last confirmed 2025-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "the topline results from FORTIFY, the Phase 3 clinical trial for BBP-418 for LGMD2I/R9 and the Company's plan to submit a New Drug Application for BBP-418 to the FDA in the first half of 2026" https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039463): "The Company intends to engage the FDA later this year to discuss these data and plans for submission of a New Drug Application (NDA) for BBP-418 in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1743881/000114036125039463/ef20057750_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "-Company intends to file an NDA for approval with the FDA in first half of 2026" https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-25-000010): "•BridgeBio intends to file a New Drug Application (NDA) for approval with the FDA in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm

### March 30, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2026-05-07, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001743881-26-000034): "•On March 30, 2026, we submitted our NDA to the FDA for oral BBP-418 for the treatment of LGMD2I/R9." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm
- SEC Form 10-Q (accession 0001743881-26-000034): "On March 30, 2026, we submitted our New Drug Application ("NDA") to the FDA for oral BBP-418 for the treatment of LGMD2I/R9." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm
- SEC Form 10-Q (accession 0001743881-26-000027): "On March 30, 2026, we submitted our New Drug Application ("NDA") to the FDA for oral BBP-418 for the treatment of LGMD2I/R9." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000027/bbio-20260630.htm
- SEC Form 10-Q (accession 0001743881-26-000019): "On March 30, 2026, we submitted our New Drug Application to the FDA for oral BBP-418 for the treatment of LGMD2I/R9." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000019/bbio-20260331.htm

### May 27, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-05-27, last confirmed 2026-05-27.
- Press release filed with the SEC (EX-99) (accession 0001140361-26-022979): "PALO ALTO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority" https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-022979): ""With today's acceptance of our NDA, we are one step closer to the potential FDA approval of a treatment that could potentially change the progression of this disease." https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_ex99-1.htm

### late 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-02-24, last confirmed 2026-02-24.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000008): "-Positive interim Phase 3 FORTIFY results for BBP-418 in LGMD2I/R9 demonstrated a statistically significant and clinically meaningful 2.6-point NSAD improvement versus placebo at 12 months; FDA recommended pursuing traditional approval, supporting a planned 1H 2026 NDA submission and a U.S. launch anticipated in late 2026/early 2027" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm

### November 27, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-05-27, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "BBP-418 for LGMD2I/R9 PDUFA date set for November 27, 2026, with Priority Review U.S. launch upon FDA approval" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000033): "•On May 27, 2026, the FDA accepted the Company's New Drug Application (NDA) for BBP-418 and granted Priority Review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000026): "BBP-418 for LGMD2I/R9 PDUFA date set for November 27, 2026 with Priority Review Launch upon FDA approval" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000026): "Furthermore, this was the quarter all three of our pipeline programs, BBP-418, encaleret, and infigratinib, moved from data into active regulatory review, with our first PDUFA date now set for November 27, 2026, which is a level of strategic execution and discipline I'm proud of." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000026): "•On May 27, 2026, the FDA accepted the Company's New Drug Application (NDA) for BBP-418 and granted Priority Review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-022979): "Fee Act (PDUFA) target action date of November 27, 2026, and BridgeBio is poised to launch BBP-418 upon approval." https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_ex99-1.htm
- SEC Form 10-Q (accession 0001743881-26-000034): "The FDA accepted our NDA for filing, granted Priority Review and assigned a Prescription Drug User Fee Act ("PDUFA") target action date of November 27, 2026, for BBP-418." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm
- SEC Form 10-Q (accession 0001743881-26-000027): "On May 27, 2026, the FDA accepted our NDA for filing, granted Priority Review and assigned a Prescription Drug User Fee Act ("PDUFA") target action date of November 27, 2026 for BBP-418." https://www.sec.gov/Archives/edgar/data/1743881/000174388126000027/bbio-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-022979): "- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval;" https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-035055): "The Company's approved medicine, Attruby, is available to people with transthyretin amyloid cardiomyopathy, and the Company has three additional medicines under FDA review, each for a genetic condition with limited or no approved treatment options: BBP-418 for limb-girdle muscular dystrophy type 2I/R9, or LGMD2I/R9 (PDUFA date with Priority Review: November 27, 2026); encaleret for autosomal dominant hypocalcemia type 1, or ADH1 (PDUFA date with Priority Review: May 7, 2027); and infigratinib for achondroplasia." https://www.sec.gov/Archives/edgar/data/1743881/000114036126035055/ef20081330_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001743881-26-000026): "- All three planned NDAs are now submitted to the FDA: BBP-418 for LGMD2I/R9 was accepted with Priority Review (PDUFA November 27, 2026); encaleret for ADH1 was accepted with Priority Review (PDUFA May 8, 2027), with no advisory committee planned for either; oral infigratinib for achondroplasia has been submitted, with U.S. launch expected mid-2027" https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ribitol.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ribitol PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ribitol

```bibtex
@misc{secapidev_pdufa_ribitol_20261116,
  title        = {Ribitol PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ribitol}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ribitol_20261116","title":"Ribitol PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ribitol","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
